Analysts forecast that Stealth BioTherapeutics Corp (NASDAQ:MITO) will report earnings per share (EPS) of ($0.07) for the current quarter, Zacks reports. Zero analysts have issued estimates for Stealth BioTherapeutics’ earnings. The company is scheduled to issue its next earnings results on Wednesday, August 21st.
On average, analysts expect that Stealth BioTherapeutics will report full year earnings of ($0.26) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($0.22) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Stealth BioTherapeutics.
Stealth BioTherapeutics (NASDAQ:MITO) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.14.
Several research analysts have recently weighed in on MITO shares. Zacks Investment Research downgraded Hallmark Financial Services from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright set a $5.00 price target on Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.83.
Shares of MITO stock traded up $0.03 on Wednesday, hitting $11.38. 680 shares of the stock were exchanged, compared to its average volume of 3,259. The company has a market capitalization of $317.14 million and a price-to-earnings ratio of -8.07. Stealth BioTherapeutics has a one year low of $10.70 and a one year high of $20.99. The firm has a 50 day moving average price of $12.38.
An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC acquired a new position in shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics as of its most recent filing with the Securities and Exchange Commission. 1.09% of the stock is currently owned by institutional investors and hedge funds.
Stealth BioTherapeutics Company Profile
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Read More: How to start trading in the forex market?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.